Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Noncontiguous Stage II / III / IV Adult NHL

Optimal treatment of advanced stages of low-grade non-Hodgkin lymphoma (NHL) is controversial because of low cure rates with the current therapeutic options. Numerous clinical trials are in progress to settle treatment issues, and patients should be urged to participate. The rate of relapse is fairly constant over time, even in patients who have achieved complete response to treatment. Indeed, relapse may occur many years after treatment. Currently, no randomized trials guide clinicians about the initial choice of watchful waiting, rituximab, nucleoside analogs, alkylating agents, combination chemotherapy, radiolabeled monoclonal antibodies, or combinations of these options.[1]; [2][Level of evidence: 1iiDiii]

For patients with indolent, noncontiguous stage II and stage III non-Hodgkin lymphoma, central lymphatic radiation therapy has been proposed but is not usually recommended as a form of treatment.[3,4]

Recommended Related to Non-Hodgkin's Lymphoma

Small Lymphocytic Lymphoma

Small lymphocytic lymphoma (SLL) is a cancer that affects a type of white blood cell called a "lymphocyte," which helps your body fight infection. You may hear your doctor refer to SLL as a "non-Hodgkin's lymphoma," which is a group of cancers that affect lymphocytes. When you have SLL, too many broken lymphocytes live and multiply in your lymph nodes. These are pea-sized organs in your neck, groin, armpits, and elsewhere, that are part of your immune system. SLL tends to grow slowly. You...

Read the Small Lymphocytic Lymphoma article > >

Numerous prospective clinical trials of interferon-alpha, including SWOG-8809, have shown no consistent benefit; the role of interferon in patients with indolent lymphoma remains controversial.[5,6,7,8,9,10,11,12,13,14,15,16]

Standard Treatment Options for Indolent, Noncontiguous Stage II/III/IV Adult NHL

Standard treatment options for indolent, noncontiguous stage II/III/IV adult NHL include the following:

  1. Watchful waiting for asymptomatic patients.
  2. Rituximab.
  3. Obinutuzumab.
  4. Purine nucleoside analogs.
  5. Alkylating agents (with or without steroids).
  6. Bendamustine.
  7. Combination chemotherapy.
  8. Yttrium-90-labeled ibritumomab tiuxetan and iodine-131-labeled tositumomab.
  9. Maintenance rituximab.

Watchful waiting for asymptomatic patients

The rate of relapse is fairly constant over time, even in patients who have achieved complete responses to treatment. Indeed, relapse may occur many years after treatment. In this category, deferred treatment (i.e., watchful waiting until the patient becomes symptomatic before initiating treatment) should be considered.[2,17,18,19]

Evidence (watchful waiting):

  1. Three randomized trials compared watchful waiting with immediate chemotherapy.[18,20]; [21][Level of evidence: 1iiA]
    • All three trials showed no difference in cause-specific or overall survival (OS).
    • For patients randomly assigned to watchful waiting, the median time to require therapy was 2 to 3 years and one-third of patients never required treatment with watchful waiting (half died of other causes and half remained progression-free after 10 years).
  2. A selected group of 107 patients with advanced stage follicular lymphoma were managed with initial watchful waiting; with a median delay of 55 months, subsequent therapy resulted in equivalent freedom from treatment failure and OS compared to a similar cohort treated immediately with rituximab.[22][Level of evidence: 3iiiDiii] This implies that watchful waiting remains a relevant approach even in the rituximab era.
    Next Article:

    Today on WebMD

    stem cells
    What are they and why do we need them?
    Lung cancer xray
    See it in pictures, plus read the facts.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Do you know the symptoms?
    Vitamin D
    New Treatments For Non-Hodgkins Lymphoma
    Lifestyle Tips for Depression Slideshow
    Pets Improve Your Health